NADAC acquisition cost data for SRONYX 0.10-0.02 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 51862054501 | $0.1992 | 2022-12-21 | Rx |
| 51862054506 | $0.1992 | 2022-12-21 | Rx |
| 51862054501 | $0.1992 | 2022-12-21 | Rx |
| 51862054506 | $0.1992 | 2022-12-21 | Rx |
Generic: Levonorgestrel/Ethin.Estradiol | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $76.0K | 2,172 | 618 | $0.6059 |
| 2020 | $82.1K | 2,246 | 612 | $0.6150 |
| 2021 | $74.1K | 1,932 | 572 | $0.6058 |
| 2022 | $81.6K | 2,252 | 665 | $0.5546 |
| 2023 | $67.1K | 2,086 | 641 | $0.4832 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Massachusetts | $7.9K | 199 | 73 |
| California | $6.8K | 172 | 62 |
| New York | $6.1K | 164 | 44 |
| North Carolina | $4.1K | 138 | 40 |
| Minnesota | $3.7K | 91 | 26 |
| Florida | $3.1K | 92 | 33 |
| Texas | $2.3K | 60 | 19 |
| Pennsylvania | $2.3K | 116 | 35 |
| Ohio | $2.3K | 64 | 23 |
| South Carolina | $2.0K | 56 | 18 |
| Missouri | $1.9K | 67 | N/A |
| Michigan | $1.8K | 55 | 15 |
| Indiana | $1.8K | 52 | 17 |
| Arizona | $1.6K | 52 | 14 |
| New Jersey | $1.4K | 42 | 12 |
| Montana | $1.4K | 85 | N/A |
| Virginia | $1.3K | 42 | 16 |
| Hawaii | $1.2K | 20 | N/A |
| Illinois | $1.2K | 65 | 15 |
| Kentucky | $1.1K | 33 | N/A |
| Connecticut | $1.1K | 35 | 11 |
| Tennessee | $972.18 | 26 | N/A |
| Rhode Island | $933.59 | 23 | 12 |
| Oregon | $717.26 | 48 | N/A |
| Georgia | $714.71 | 37 | N/A |
| Maryland | $684.94 | 20 | 13 |
| Wisconsin | $668.66 | 25 | N/A |
| Alabama | $663.94 | 14 | N/A |
| West Virginia | $637.61 | 11 | N/A |
| Kansas | $604.76 | 30 | N/A |
| North Dakota | $555.84 | 14 | N/A |
| Oklahoma | $486.40 | 15 | N/A |
| New Hampshire | $370.18 | 12 | N/A |
| Maine | $300.60 | 15 | N/A |
| Vermont | $269.95 | 15 | N/A |
| Alaska | $196.63 | 15 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.